Our study also demonstrates a potential of TMEM25 for targeted therapy of TNBC, and suggests that clinical mutations of TMEM25 identified in other types of cancer may be able to trigger monomeric-EGFR/STAT3 signaling to promote tumor progression as well. The gene discussed is STAT3; the disease is neoplasm.